Form 4: MaxCyte Director William W. Brooke Reports Acquisition of Shares and Stock Options

Director William W. Brooke reports acquisition of MaxCyte shares and stock options as part of an annual equity grant.

Summary

• On June 11, 2024, William W. Brooke, a director of MaxCyte, Inc. (MXCT), reported the acquisition of 21,367 shares of common stock and 40,701 stock options.
• The shares were acquired as restricted stock units (RSUs), each representing a contingent right to receive one share of MaxCyte's common stock.
• The stock options, with an exercise price of $4.68, were granted as part of the Issuer's Equity Grant Policy for non-employee directors.
• These options vest on June 11, 2025, contingent upon the reporting person's continuous service as of that date.
• Following the reported transactions, Brooke beneficially owns 71,669 shares of common stock and 40,701 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future.
• The equity grant policy aligns the interests of non-employee directors with those of shareholders.

Future Outlook

The shares underlying the grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key individuals within the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates